India Glycols Fixes Sept 1 as Effective Date, Sept 2 as Record Date for Share Allotment
India Glycols Limited set September 1, 2026, as the Effective Date and September 2, 2026, as the Record Date for its Scheme of Arrangement. Shareholders will receive shares in Ennature Bio Pharma Limited and IGSL Spirits Limited based on their holdings in India Glycols.
The fixation of effective and record dates for a scheme of arrangement is a material event that will lead to share allotment and potential listing of new entities, impacting the company's corporate structure and shareholder value.
The announcement is a procedural update regarding a scheme of arrangement and share allotment, with no immediate financial impact or significant positive/negative news conveyed.
India Glycols Limited has announced the fixation of the Effective Date and Record Date for the allotment of shares pursuant to a Scheme of Arrangement. The Board of Directors, through a resolution passed by circulation on August 21, 2026, has set Tuesday, September 1, 2026, as the Effective Date.
This Effective Date is when the certified true copy of the National Company Law Tribunal's (NCLT) order sanctioning the Scheme of Arrangement will be filed with the Registrar of Companies. The Scheme involves India Glycols Limited (Demerged Company), Ennature Bio Pharma Limited (Resulting Company 1/EBL), and IGSL Spirits Limited (Resulting Company 2/IGSL).
Furthermore, Wednesday, September 2, 2026, has been fixed as the Record Date. This date will be used to determine the shareholders eligible for the allotment of shares in Resulting Company 1 and Resulting Company 2. For Resulting Company 1, shareholders holding 3 equity shares of INR 5 face value each in India Glycols Limited will receive 1 equity share of INR 5 face value. For Resulting Company 2, shareholders holding 1 equity share of INR 5 face value each will receive 1 equity share of INR 5 face value.
The equity shares to be allotted by both Resulting Companies will be listed on the National Stock Exchange of India Limited and the BSE Limited, subject to regulatory approvals.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.